Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

There’s something special about seeing a play or musical in its infancy, perhaps at the workshop stage or shortly after its premiere. There’s something extra special then about seeing the world ...

They expect to submit to the FDA for approval for weight loss before the end of the year, and for diabetes treatment in 2026.

How Healthletic’s USP-Grade Methylene Blue Drops Are Revolutionizing Brain Energy, Focus, and Cognitive Vitality in 2025New ...